Literature DB >> 24170022

[Current status of carotid endarterectomy].

M Storck1.   

Abstract

Carotid endarterectomy (CEA) has been evaluated in many prospective randomized studies. After the introduction of carotid stenting (CAS) an alternative treatment is now available for treatment of extracranial carotid stenoses. Comparative studies have been carried out to compare these two modalities. There are two general methods for operative reconstruction available: patch angioplasty and endarterectomy. The results of the mandatory quality assurance registry between the time period 2003-2011 showed a reduction in complication rates, more operations in regional anesthesia and a higher percentage of eversion endarterectomy during the observation period. Since 2012 CAS is now also included in the national quality assurance program.

Mesh:

Year:  2013        PMID: 24170022     DOI: 10.1007/s00059-013-3972-2

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  3 in total

1.  Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial).

Authors:  David J Cohen; Joshua M Stolker; Kaijun Wang; Elizabeth A Magnuson; Wayne M Clark; Bart M Demaerschalk; Albert D Sam; James R Elmore; Fred A Weaver; Herbert D Aronow; Larry B Goldstein; Gary S Roubin; George Howard; Thomas G Brott
Journal:  J Am Coll Cardiol       Date:  2011-10-04       Impact factor: 24.094

2.  Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes.

Authors:  Konstantinos P Economopoulos; Theodoros N Sergentanis; Georgios Tsivgoulis; Anargiros D Mariolis; Christodoulos Stefanadis
Journal:  Stroke       Date:  2011-01-13       Impact factor: 7.914

Review 3.  The diagnosis, treatment and follow-up of extracranial carotid stenosis.

Authors:  Hans-Henning Eckstein; Andreas Kühnl; Arnd Dörfler; Ina B Kopp; Holger Lawall; Peter A Ringleb
Journal:  Dtsch Arztebl Int       Date:  2013-07-08       Impact factor: 5.594

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.